Following a significant statement on its advancements in AI-enhanced drug development, shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) saw a large after-hours surge, rising 19.07% to $5.37.
Strategic Partnership Enhance Screening Capabilities
Using its in-house Recursion OS and Enamine’s vast REAL Space, the biggest collection of make-on-demand small molecules in the world, Recursion (RXRX) announced the successful creation of focused screening libraries in partnership with Enamine. Ten highly enriched chemical libraries have been curated as a result of RXRX and Enamine’s partnership.
These libraries, which are based on more than 15,000 recently synthesized chemicals, are intended to speed up the process of finding treatments for 100 difficult and clinically relevant therapeutic targets. The search for cures for diseases with intricate biological processes has advanced significantly as a result of this endeavor.
Merging AI with Vast Chemical Space
Enamine’s REAL Space is a continuously expanding chemical collection shaped by insights from millions of parallel syntheses. The enormous volume of possible compounds—tens of billions—makes effective selection difficult.
The collaboration enables the creation of small, highly targeted libraries by fusing this enormous chemical world with Recursion OS’s predictive powers. These targeted collections are expected to significantly outperform traditional high-throughput screening (HTS) approaches.
Extending Innovation Beyond Internal Discovery
While Recursion has already leveraged this technology internally, the collaboration now enables broader application across areas of biological interest to the wider pharmaceutical industry. RXRX’s integration of its AI-powered platform with Enamine’s massive chemical archive presents a potent tool for future drug discovery efforts.
As part of the agreement, the company also gained access to thousands of compounds previously outside its existing 1.2 million compound library, in return for assisting Enamine in building commercially viable libraries.
Scaling Virtual Screening Across Diverse Targets
Although Enamine’s REAL Space has previously supported large-scale virtual screening campaigns, this marks the first time it has been systematically explored across multiple biological targets at scale.
The partnership with Recursion empowers Enamine to deliver a new generation of compound libraries, with rapid access to analogues, aimed at accelerating customers’ early-stage hit-finding campaigns.
